Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Novartis Ireland Limited .
Filed returns
70
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2023 | Novartis Ireland Limited | Health | Concerns over Europe’s competitiveness regarding proposals on the revision of the EU Pharmaceutical Legislation (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Novartis Ireland Limited | Health | The Pharma Industry in Ireland ask for government support to reform the reimbursement process as Irish patients lagging behind EU counterparts in terms of access to medicines (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2022 | Novartis Ireland Limited | Health | Update of SmartD8 Heart of Our City Social Prescribing Project. Discussion on national Illness/wellness festival with Healthy Ireland support. Partnerships/collaborations to support the Healthcare system. (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2021 | Novartis Ireland Limited | Health | New born screening, timely access to new medicines in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Novartis Ireland Limited | Health | Expansion of Newborn Screening (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2020 | Novartis Ireland Limited | Health | Timely access to innovative new products, IP, EU Pharma Strategy (Legislation) | 1 | On lobbying.ie |
| May–Aug 2020 | Novartis Ireland Limited | Health | Supporting intellectual property incentives in rare diseases, funding for new medicines, EU Pharmaceutical Strategy, (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2019 | Novartis Ireland Limited | Health | Reimbursement of new Medicines, Intellectual Property, need for new approaches in cell & gene therapy (Matters involving public funds) | 4 | On lobbying.ie |
| Jan–Apr 2019 | Novartis Ireland Limited | Health | Timely access to innovative new medicines (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2018 | Novartis Ireland Limited | Health | Government support for maintaining current EU incentives on intellectual property which is being re-examined at a European level. (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2018 | Novartis Ireland Limited | Health | Strong Intellectual Property protection is a critical pre-requisite to maintaining an environment where innovation can thrive in healthcare (Legislation) | 1 | On lobbying.ie |
| May–Aug 2017 | Novartis Ireland Limited | Health | Highlight delay in reimbursing Entresto (Heart Failure medine), the first new innovation in heart failure in a decade considered cost effective in July 2016 (Matters involving public funds) | 23 | On lobbying.ie |
| Jan–Apr 2017 | Novartis Ireland Limited | Health | Ensure a competitive pro-business environment, that supports innovative medicines (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2016 | Novartis Ireland Limited | Health | Making Heart Failure a public policy priority (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2016 | Novartis Ireland Limited | Health | Support MS & Employment initiative so that people with MS can be productive members of the workforce (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2016 | Novartis Ireland Limited | Health | Ensure that the 2016 Framework Agreement on the Pricing and Supply of Medicines is resolved by aggreement, not legislation (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2016 | Novartis Ireland Limited | Health | Make heart failure (HF) a health policy priority - update on initiatives taking place in the West (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2016 | Novartis Ireland Limited | Health | Promoting a business and healthcare environment that is innovation focused (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2015 | Novartis Ireland Limited | Health | Highlighting the societal cost of multiple scelerosis (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2015 | Novartis Ireland Limited | Health | Making heart failure a national priority (Public policy or programme) | 19 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 62 | 88.6% | |
| Environment | 4 | 5.7% | |
| Foreign Affairs | 2 | 2.9% | |
| EU Affairs | 1 | 1.4% | |
| Justice and Equality | 1 | 1.4% |